Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition

Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?

(2016) Piera Gargiulo et al.   CANCER TREATMENT REVIEWS

Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer

(2016) Hui Zhang et al.   CELL

Regression of Chemotherapy-Resistant Polymerase   (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab

(2016) A. D. Santin et al.   CLINICAL CANCER RESEARCH

Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis

(2016) M. K. McConechy et al.   CLINICAL CANCER RESEARCH

Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer

(2016) D. R. Kroeger et al.   CLINICAL CANCER RESEARCH

CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma

(2016) Hagma H. Workel et al.   EUROPEAN JOURNAL OF CANCER

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability

(2016) Bernhard Mlecnik et al.   IMMUNITY

Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers

(2016) Marie-Caroline Dieu-Nosjean et al.   IMMUNOLOGICAL REVIEWS

Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence

(2016) Caroline C. Billingsley et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

(2016) Janice M. Mehnert et al.   JOURNAL OF CLINICAL INVESTIGATION

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency

(2016) Eric Bouffet et al.   JOURNAL OF CLINICAL ONCOLOGY

Climate change and non-communicable diseases

(2016) The Lancet Oncology   LANCET ONCOLOGY

Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer

(2016) Inge C Van Gool et al.   MODERN PATHOLOGY

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

(2016) Alena Gros et al.   NATURE MEDICINE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer

(2016) Ellen Stelloo et al.   Oncotarget

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

(2016) Marios Giannakis et al.   Cell Reports

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

(2016) Joseph McLaughlin et al.   JAMA Oncology

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

(2015) I. C. van Gool et al.   CLINICAL CANCER RESEARCH

PD-L1 expression in small cell neuroendocrine carcinomas

(2015) Anne M. Schultheis et al.   EUROPEAN JOURNAL OF CANCER

Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients

(2015) Stefania Bellone et al.   GYNECOLOGIC ONCOLOGY

Histopathological features of endometrial carcinomas associated withPOLEmutations: implications for decisions about adjuvant therapy

(2015) Salwa Bakhsh et al.   HISTOPATHOLOGY

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

(2015) Ellen Stelloo et al.   MODERN PATHOLOGY

SomaticPOLEmutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis

(2015) E. Zeynep Erson-Omay et al.   NEURO-ONCOLOGY

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2015) Timothy A. Chan et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity

(2015) Claire Germain et al.   Frontiers in Immunology

POLE proofreading mutation, immune response and prognosis in endometrial cancer

(2015) Inge C. van Gool et al.   OncoImmunology

Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1

(2015) Brooke E. Howitt et al.   JAMA Oncology

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

(2014) S. D. Brown et al.   GENOME RESEARCH

Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication

(2014) Eve Shinbrot et al.   GENOME RESEARCH

Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity

(2014) Fei Duan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer

(2014) David N. Church et al.   JNCI-Journal of the National Cancer Institute

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

High and Interrelated Rates of PD-L1+CD14+ Antigen-Presenting Cells and Regulatory T Cells Mark the Microenvironment of Metastatic Lymph Nodes from Patients with Cervical Cancer

(2014) A. M. Heeren et al.   Cancer Immunology Research

DNA polymerase ɛ and δ exonuclease domain mutations in endometrial cancer

(2013) David N. Church et al.   HUMAN MOLECULAR GENETICS

Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

(2013) Nienke van Rooij et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrated genomic characterization of endometrial carcinoma

(2013) Gad Getz et al.   NATURE

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation analysis

(2012) Ronald van Eijk et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

In silico prediction of tumor antigens derived from functional missense mutations of the cancer gene census

(2012) Jahan S. Khalili et al.   OncoImmunology

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients?

(2008) E. S. Jordanova et al.   CLINICAL CANCER RESEARCH